The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Self-citationMcArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70012-9 · Cited by 977
Self-citation
Research works printed but not linked: 13
- Davies, 2011, Prognostic factors for survival in melanoma patients with brain metastases, Cancer, 117, 1687, 10.1002/cncr.25634 · DOI · Paper page
- Fife, 2004, Determinants of outcome in melanoma patients with cerebral metastases, J Clin Oncol, 22, 1293, 10.1200/JCO.2004.08.140 · DOI · Paper page
- Eigentler, 2011, Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma, Cancer, 117, 1697, 10.1002/cncr.25631 · doi:10.1002/cncr.25631
- Goyal, 2015, Clinical management of multiple melanoma brain metastases: a systematic review, JAMA Oncol, 1, 668, 10.1001/jamaoncol.2015.1206 · DOI
- Douglas, 2002, The treatment of brain metastases from malignant melanoma, Semin Oncol, 29, 518, 10.1053/sonc.2002.35247 · doi:10.1053/sonc.2002.35247
- Agarwala, 2004, Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study, J Clin Oncol, 22, 2101, 10.1200/JCO.2004.11.044 · DOI · Paper page
- Avril, 2004, Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study, J Clin Oncol, 22, 1118, 10.1200/JCO.2004.04.165 · DOI · Paper page
- Long, 2015, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, Lancet, 386, 444, 10.1016/S0140-6736(15)60898-4 · DOI · Paper page
- Ascierto, 2016, Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials, Lancet Oncol, pii, S1470
- Long, 2012, Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, Lancet Oncol, 13, 1087, 10.1016/S1470-2045(12)70431-X · DOI · Paper page
- Dummer, 2014, Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study, Eur J Cancer, 50, 611, 10.1016/j.ejca.2013.11.002 · DOI · Paper page
- Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868 · DOI · Paper page
- Chen, 2014, Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target, Clin Can Res, 20, 5537, 10.1158/1078-0432.CCR-13-3003 · DOI · Paper page
Cited by
Long, G. V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A. D., Brown, M. P., Wilmott, J. S., Edwards, J., Gonzalez, M., Scolyer, R. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30139-6 · Cited by 987
Self-citationTreatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Vogelbaum, M. A., Brown, P. D., Messersmith, H., Brastianos, P. K., Burri, S., Cahill, D., Dunn, I. F., Gaspar, L. E., Gatson, N. T. N., Gondi, V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02314 · Cited by 832
Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637
Le Rhun, E., Guckenberger, M., Smits, M., Dummer, R., Bachelot, T., Sahm, F., Galldiks, N., de Azambuja, E., Berghoff, A. S., Metellus, P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.016 · Cited by 592
Self-citationCurrent approaches to the management of brain metastases
Suh, J. H., Kotecha, R., Chao, S. T., Ahluwalia, M. S., Sahgal, A., & Chang, E. L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0320-3 · Cited by 553
Metadata
- Authors
- McArthur, G. A., Maio, M., Arance, A., Nathan, P., Blank, C., Avril, M.-F., Garbe, C., Hauschild, A., Schadendorf, D., Hamid, O., Fluck, M., Thebeau, M., Schachter, J., Kefford, R., Chamberlain, M., Makrutzki, M., Robson, S., Gonzalez, R., & Margolin, K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 28
- Issue
- 3
- Pages
- 634-641
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2562656839
- Cited by
- 251
- References
- 3
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 973 d)
- Funders
- F. Hoffmann-La Roche Ltd
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. https://app.cochat.ai/papers/10.1093/annonc/mdw641
- The paper
- McArthur, G. A., Maio, M., Arance, A., Nathan, P., Blank, C., Avril, M.-F., Garbe, C., Hauschild, A., Schadendorf, D., Hamid, O., Fluck, M., Thebeau, M., Schachter, J., Kefford, R., Chamberlain, M., Makrutzki, M., Robson, S., Gonzalez, R., & Margolin, K. (2017). Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Annals of Oncology. https://doi.org/10.1093/annonc/mdw641
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.